SCHEMBL16987294

SCHEMBL16987294

COc1cccc(C(OC(c2ccccc2)(c2cccc(OC)c2)c2ccccc2OC)(c2ccccc2)c2ccccc2OC)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.43
NFE2L2 Q16236 1/20 0.40
MAPK1 P28482 1/20 0.39
CA4 P22748 1/20 0.38
HRH4 Q9H3N8 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
MAOB P27338 1/20 0.37
ACHE P22303 1/20 0.37
CYP1A1 P04798 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP1B1 Q16678 1/20 0.36
NPC1 O15118 2/20 0.36
MEN1 O00255 2/20 0.36
GAA P10253 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
RAB9A P51151 1/20 0.36
NLRP3 Q96P20 1/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022976 0.87 CA1 (0.46) NFE2L2MAPK1CA4MEN1GAA
SCHEMBL1093934 0.85 KIF11 (0.50) KIF11CA4MAOBACHECYP1A2
SCHEMBL136228 0.84 CA1 (0.46) NFE2L2MAPK1CA4MEN1GAA
SCHEMBL136230 0.79 NFE2L2 (0.44) NFE2L2CA4NPC1ABCB1CA1
SCHEMBL31430103 0.79 NFE2L2 (0.44) NFE2L2CA4NPC1ABCB1CA1
SCHEMBL6257499 0.77 CA1 (0.46) NFE2L2MAPK1CA4MEN1GAA
SCHEMBL7713128 0.77 CA1 (0.46) NFE2L2MAPK1CA4MEN1GAA
SCHEMBL4660364 0.76 CA1 (0.55) MAPK1CA4MEN1GAAKMT2A
SCHEMBL2368143 0.75 NR3C2 (0.42) CA4MEN1GAAKMT2AALDH1A1
SCHEMBL5583968 0.74 CA1 (0.43) KIF11NFE2L2MAPK1CA4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10414790-B2 Exocyclic nitrogen atom protected nucleoside and method for producing and using the same THE REGENTS OF THE UNIVERSITY OF COLORADO (US) 2019-09-17 US disclosed
US-20150225442-A1 EXOCYLIC NITROGEN ATOM PROTECTED NUCLEOSIDE AND METHOD FOR PRODUCING AND USING THE SAME THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) 2015-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10414790-B2 Exocyclic nitrogen atom protected nucleoside and method for producing and using the same NT5C3B, RNGTT, UMPS KIF11 3264/4885NFE2L2 3007/4885MAPK1 2529/4885
US-20150225442-A1 EXOCYLIC NITROGEN ATOM PROTECTED NUCLEOSIDE AND METHOD FOR PRODUCING AND USING THE SAME NSUN2, RNGTT, NT5C3B KIF11 2806/4885NFE2L2 2221/4885MAPK1 3766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.